



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K	A2	(11) International Publication Number: WO 95/21601 (43) International Publication Date: 17 August 1995 (17.08.95)
(21) International Application Number: PCT/US95/00299 (22) International Filing Date: 11 January 1995 (11.01.95) (30) Priority Data: 08/179,964 11 January 1994 (11.01.94) US 08/208,264 10 March 1994 (10.03.94) US (60) Parent Application or Grant (63) Related by Continuation US 08/208,264 (CIP) Filed on 10 March 1994 (10.03.94) (71) Applicant (for all designated States except US): PROTEIN ENGINEERING CORPORATION [US/US]; 765 Concord Avenue, Cambridge, MA 02138 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MARKLAND, William [GB/US]; 26 Windsor Road, Milford, MA 01757 (US). LADNER, Robert, Charles [US/US]; 3827 Green Valley Road, Ijamsville, MD 21754 (US). (74) Agent: COOPER, Iver, P.; Browdy and Neimark, 419 Seventh Street, N.W. #300, Washington, DC 20004 (US).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: KALLIKREIN-INHIBITING "KUNITZ DOMAIN" PROTEINS AND ANALOGUES THEREOF (57) Abstract This invention relates to novel BPTI-homologous Kunitz domains, especially LACI homologues, which inhibit one or more plasma (and/or tissue) kallikreins, and to the therapeutic and diagnostic use of these novel proteins. In particular, this invention relates to Kunitz domains derived from Kunitz domains of human origin and especially to the first Kunitz domain of LACI.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

KALLIKREIN-INHIBITING "KUNITZ DOMAIN" PROTEINS AND ANALOGUES THEREOF

5

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to novel classes of proteins and protein analogues which bind to and inhibit human plasma kallikrein.

10 Description of the Background Art

Kallikreins are serine proteases found in both tissues and plasma. Plasma kallikrein is involved in contact-activated (intrinsic pathway) coagulation, fibrinolysis, hypotension, and inflammation. (See BH0092). These effects of kallikrein are mediated through the activities of three distinct physiological substrates: i) Factor XII (coagulation), ii) Pro-urokinase/plasminogen (fibrinolysis),
15 and iii) Kininogens (hypotension and inflammation).

Kallikrein cleavage of kininogens results in the production of kinins, small highly potent bioactive peptides. The kinins act through cell surface receptors present on a variety of cell types. Intracellular heterotrimeric G-proteins link the kinin receptors to second messenger pathways including nitric oxide, adenylyl cyclase, phospholipase A₂, and phospholipase C. Among the
20 significant physiological activities of kinins are: (i) increased vascular permeability; (ii) vasodilation; (iii) bronchospasm; and (iv) pain induction. Thus, kinins mediate the life-threatening vascular shock and edema associated with bacteremia (sepsis) or trauma, the edema and airway hyperreactivity of asthma, and both inflammatory and neurogenic pain associated with tissue injury. The consequences of inappropriate plasma kallikrein activity and resultant kinin production
25 are dramatically illustrated in patients with hereditary angioedema (HA). HA is due to a genetic deficiency of C1-inhibitor, the principal endogenous inhibitor of plasma kallikrein. Symptoms of HA include edema of the skin, subcutaneous tissues and gastrointestinal tract, and abdominal pain and vomiting. Nearly one-third of HA patients die by suffocation due to edema of the larynx and upper respiratory tract. Kallikrein is secreted as a zymogen (prekallikrein) that circulates as an
30 inactive molecule until activated by a proteolytic event that frees the +NH₂-IVGGTNSS... sequence of kallikrein (SEQ ID NO. 1). Human Plasma Prekallikrein is found in Genebank entry

P03952.

Mature plasma Kallikrein contains 619 amino acids. Hydrolysis of the Arg₃₇₁-Ile₃₇₂ peptide bond yields a two-chain proteinase joined by a disulfide bond. The amino-terminal light chain (248 residues) carries the catalytic site.

5 The main inhibitor of plasma kallikrein (pKA) *in vivo* is the C1 inhibitor; see SCHM87, pp.27-28. C1 is a serpin and forms an essentially irreversible complex with pKA. Although bovine pancreatic trypsin inhibitor (BPTI) was first said to be a strong pKA inhibitor with $K_i = 320$ pM (AUER88), BERN93 indicates that its K_i for pKA is 30 nM (*i.e.*, 30,000 pM). The G36S mutant had a K_i of over 500 nM. Thus, there is a need for a safe kallikrein inhibitor. The essential
10 attributes of such an agent are:

- i. Neutralization of relevant kallikrein enzyme(s);
- ii. High affinity binding to target kallikreins to minimize dose;
- iii. High specificity for kallikrein, to reduce side effects; and
- iv. High degree of similarity to a human protein to minimize potential
15 immunogenicity and organ/tissue toxicity.

The candidate target kallikreins to be inhibited are chymotrypsin-homologous serine proteases.

Excessive Bleeding

Excessive bleeding can result from deficient coagulation activity, elevated fibrinolytic activity, or a combination of the two. In most diatheses one must control the activity of plasmin. However,
20 plasma kallikrein (pKA) is an activator of plasminogen and a potent, selective pKA inhibitor may avert plasminogen activation. The clinically beneficial effect of BPTI in reducing blood loss is thought to result from its inhibition of plasmin ($K_D \sim 0.3$ nM) or of plasma kallikrein ($K_D \sim 100$ nM) or both enzymes. It has been found, however, that BPTI is sufficiently antigenic that second uses require skin testing. Furthermore, the doses of BPTI required to control bleeding are quite
25 high and the mechanism of action is not clear. Some say that BPTI acts on plasmin while others say that it acts by inhibiting plasma kallikrein. FRAE89 reports that doses of about 840 mg of BPTI to 80 open-heart surgery patients reduced blood loss by almost half and the mean amount transfused was decreased by 74%. Miles Inc. has recently introduced Trasylol in USA for reduction of bleeding in surgery (See Miles product brochure on Trasylol, which is hereby
30 incorporated by reference.) LOHM93 suggests that plasmin inhibitors may be useful in controlling bleeding in surgery of the eye. SHER89 reports that BPTI may be useful in limiting

bleeding in colonic surgery.

A kallikrein inhibitor that is much more potent than BPTI and that is almost identical to a human protein domain offers similar therapeutic potential, allows dose to be reduced, and poses less potential for antigenicity.

5 With recombinant DNA techniques, one may obtain a novel protein by expression of a mutated gene of a parental protein. Several strategies are known for picking mutations to test. One, "protein surgery", involves the introduction of one or more predetermined mutations within the gene of choice. A single polypeptide of completely predetermined sequence is expressed, and its binding characteristics are evaluated.

10 At the other extreme is random mutagenesis by means of relatively nonspecific mutagens such as radiation and various chemical agents, see Lehtovaara, E.P. Appln. 285,123, or by expression of highly degenerate DNA. It is also possible to follow an intermediate strategy in which some residues are kept constant, others are randomly mutated, and still others are mutated in a predetermined manner. This is called "variegation". See Ladner, et al. USP 5,220,409.

15 DENN94a and DENN94b report selections of Kunitz domains based on APP-I for binding to the complex of Tissue Factor with Factor VII_a. They did not use LACI-K1 as parental and did not use pKA as a target. The highest affinity binder they obtained had K_D for their target of about 2 nM. Our first-round selectants for binding to pKA have affinity of about 0.3 nM, and our second round selectants are about at 0.1 nM (= 100 pM) or better.

20 Proteins taken from a particular species are assumed to be less likely to cause an immune response when injected into individuals of that species. Murine antibodies are highly antigenic in humans. "Chimeric" antibodies having human constant domains and murine variable domains are decidedly less antigenic. So called "humanized" antibodies have human constant domains and variable domains in which the CDRs are taken from murine antibodies while the framework of the
25 variable domains are of human origin. "Humanized" antibodies are much less antigenic than are "chimeric" antibodies. In a "humanized" antibody, fifty to sixty residues of the protein are of non-human origin. The proteins of this invention comprise, in most cases, only about sixty amino acids and usually there are ten or fewer differences between the engineered protein and the parental protein. Although humans do develop antibodies even to human proteins, such as human insulin,
30 such antibodies tend to bind weakly and the often do not prevent the injected protein from displaying its intended biological function. Using a protein from the species to be treated does

not guarantee that there will be no immune response. Nevertheless, picking a protein very close in sequence to a human protein greatly reduces the risk of strong immune response in humans.

Kunitz domains are highly stable and can be produced efficiently in yeast or other host organisms. At least ten human Kunitz domains have been reported. Although BPTI was thought
5 at one time to be a potent pKA inhibitor, there are, actually, no human Kunitz domains that inhibits pKA very well. Thus, it is a goal of this invention to provide sequences of Kunitz domain that are both potent inhibitors of pKA and close in sequence to human Kunitz domains.

The use of site-specific mutagenesis, whether nonrandom or random, to obtain mutant binding proteins of improved activity, is known in the art, but does not guarantee that the mutant
10 proteins will have the desired target specificity or affinity. Given the poor anti-kallikrein activity of BPTI, mutation of BPTI or other Kunitz domain proteins would not have been considered, prior to this invention, a preferred method of obtaining a strong binder, let alone inhibitor, of kallikrein.

15 SUMMARY OF THE INVENTION

This invention relates to novel BPTI-homologous Kunitz domains, especially LACI homologues, which inhibit one or more plasma (and/or tissue) kallikreins, and to the therapeutic and diagnostic use of these novel proteins. In particular, this invention relates to Kunitz domains derived from Kunitz domains of human origin and especially to the first Kunitz domain of LACI; Kunitz
20 domains of human origin are likely to be non-immunogenic in humans. The proteins of this invention inhibit plasma kallikrein (and/or tissue kallikrein) with a K_D of no more than 20 nM, preferably, no more than 5 nM, more preferably, no more than about 300 pM, and most preferably, no more than about 100 pM.

A specific, high affinity inhibitor of plasma kallikrein (and, where needed, tissue kallikrein)
25 will demonstrate significant therapeutic utility in all pathological conditions mediated by kallikrein, and especially those associated with kinins. The therapeutic approach of inhibiting the catalytic production of kinins is considered preferable to antagonism of kinin receptors, since in the absence of kallikrein inhibition, receptor antagonists must compete with continuous kinin generation. Significantly, genetic deficiency of plasma kallikrein is benign and thus, inhibition of plasma
30 kallikrein is likely to be safe. We have recently discovered a lead pKA inhibitor, designated KKII/3#6. This inhibitor is a variant of a naturally occurring human plasma protein Kunitz domain

and demonstrates significantly greater kallikrein binding potency than Trasylol. KKII/3#6 has a K_i for kallikrein which is over 100 times that of both wild-type LACI and of BPTI, and is about 300 pM. In contrast, its K_i for plasmin is 10 μ M. Proteins KK2/#11 and KK2/#13 are especially preferred pKA inhibitors and have $K_i < 300$ pM and probably less than 100 pM. A reversible inhibitor is believed to be of greater utility than an irreversible inhibitor such as the C1 inhibitor.

Transfer of the subsequences that confer pKA binding into other Kunitz domains, particularly human Kunitz domains is disclosed.

The preferred pKA inhibitors of the present invention fulfill one or more of the following desiderata:

- 1) the inhibitor inhibits plasma kallikrein with a K_i no more than 20 nM, preferably 5 nM or less, more preferably 300 pM or less, and most preferably 100 pM or less,
- 2) the inhibitor comprise a Kunitz domain meeting the requirements shown in Table 14 with residues number by reference to BPTI,
- 3) the inhibitor has at the Kunitz domain positions 12-21 and 32-39 one of the amino-acid types listed for that position in Table 15, and
- 4) the inhibitor is substantially homologous to a reference sequence of essentially human origin selected from the group KKII/3#6, KK2/#11, KK2/#13, KK2/#1, KK2/#2, KK2/#3, KK2/#4, KK2/#6, KK2/#7, KK2/#8, KK2/#9, KK2/#10, KK2/#12, KK2con1, Human LACI-K2, Human LACI-K3, Human collagen α 3 KuDom, Human TFPI-2 DOMAIN 1, Human TFPI-2 DOMAIN 2, Human TFPI-2 DOMAIN 3, HUMAN ITI-K1, Human ITI-K2, HUMAN PROTEASE NEXIN-II, Human APP-I, DKI-1.2.1, DKI-1.3.1, DKI-2.1, DKI-3.1.1, DKI-3.2.1, DKI-3.3.1, DKI-4.1.1, DKI-4.2.1, DKI-4.2.2, DKI-5.1, and DKI-6.1

NOMENCLATURE

Herein, affinities are stated as K_D ($K_D(A,B)=[A][B]/[A-B]$). A numerically smaller K_D reflects higher affinity. For the purposes of this invention, a "kallikrein inhibiting protein" is one that binds and inhibits a specified kallikrein with K_i of about 20 nM or less. "Inhibition" refers to blocking the catalytic activity of kallikrein and so is measurable *in vitro* in assays using chromogenic or fluorogenic substrates or in assays involving macromolecules.

Amino-acid residues are discussed in three ways: full name of the amino acid, standard

three-letter code, and standard single-letter code. The text uses full names and three-letter code where clarity requires.

A = Ala	G = Gly	M = Met	S = Ser
C = Cys	H = His	N = Asn	T = Thr
D = Asp	I = Ile	P = Pro	V = Val
E = Glu	K = Lys	Q = Gln	W = Trp
F = Phe	L = Leu	R = Arg	Y = Tyr

For the purposed of this invention, "**substantially homologous**" sequences are at least 51%, more preferably at least 80%, identical, over any specified regions. For this invention, "substantially homologous" includes exact identity. Sequences would still be "substantially homologous" if within one region of at least 20 amino acids they are sufficiently similar (51% or more) but outside the region of comparison they differed totally. An insertion of one amino acid in one sequence relative to the other counts as one mismatch. Most preferably, no more than six residues, other than at termini, are different. Preferably, the divergence in sequence, particularly in the specified regions, is in the form of "conservative modifications".

"**Conservative modifications**" are defined as

- (a) conservative substitutions of amino acids as defined in Table 9; and
- (b) single or multiple insertions or deletions of amino acids at termini, at domain boundaries, in loops, or in other segments of relatively high mobility.

Preferably, except at termini, no more than about six amino acids are inserted or deleted at any locus, and the modifications are outside regions known to contain important binding sites.

Kunitz Domains

Herein, "**Kunitz domain**" and "**KuDom**" are used interchangeably to mean a homologue of BPTI (not of the Kunitz soya-bean trypsin inhibitor). A KuDom is a domain of a protein having at least 51 amino acids (and up to about 61 amino acids) containing at least two, and preferably three, disulfides. Herein, the residues of **all Kunitz domains are numbered by reference to BPTI** (i.e. residues 1-58, amino-acid sequence in Table 2). Thus the first cysteine residue is residue 5 and the last cysteine is 55. An amino-acid sequence shall, for the purposed of this invention, be deemed a Kunitz domain if it can be aligned, with three or fewer mismatches, to the sequence shown in Table 14. An insertion or deletion of one residue shall count as one mismatch. In Table

14, "x" matches any amino acid and "X" matches the types listed for that position. Disulfides bonds link at least two of: 5 to 55, 14 to 38, and 30 to 51. The number of disulfides may be reduced by one, but none of the standard cysteines shall be left unpaired. Thus, if one cysteine is changed, then a compensating cysteine is added in a suitable location or the matching cysteine is also replaced by a non-cysteine (the latter being generally preferred). For example, *Drosophila* *funnebris* male accessory gland protease inhibitor has no cysteine at position 5, but has a cysteine at position -1 (just before position 1); presumably this forms a disulfide to CYS₅₅. If Cys₁₄ and Cys₃₈ are replaced, the requirement of Gly₁₂, (Gly or Ser)₃₇, and Gly₃₆ are dropped. From zero to many residues, including additional domains (including other KuDoms), can be attached to either end of a Kunitz domain.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Protease inhibitors, such as Kunitz domains, function by binding into the active site of the protease so that a peptide bond (the "scissile bond") is: 1) not cleaved, 2) cleaved very slowly, or 3) cleaved to no effect because the structure of the inhibitor prevents release or separation of the cleaved segments. In Kunitz domains, disulfide bonds act to hold the protein together even if exposed peptide bonds are cleaved. From the residue on the amino side of the scissile bond, and moving away from the bond, residues are conventionally called P1, P2, P3, *etc.* Residues that follow the scissile bond are called P1', P2', P3', *etc.* (SCHE67, SCHE68). It is generally accepted that each serine protease has sites (comprising several residues) S1, S2, *etc.* that receive the side groups and main-chain atoms of residues P1, P2, *etc.* of the substrate or inhibitor and sites S1', S2', *etc.* that receive the side groups and main-chain atoms of P1', P2', *etc.* of the substrate or inhibitor. It is the interactions between the S sites and the P side groups and main chain atoms that give the protease specificity with respect to substrates and the inhibitors specificity with respect to proteases. Because the fragment having the new amino terminus leaves the protease first, many worker designing small molecule protease inhibitors have concentrated on compounds that bind sites S1, S2, S3, *etc.*

LASK80 reviews protein protease inhibitors. Some inhibitors have several reactive sites on one polypeptide chain, and these domains usually have different sequences, specificities, and even topologies. It is known that substituting amino acids in the P₃ to P₃' region influences the specificity of an inhibitor. Previously, attention has been focused on the P1 residue and those very close to it because these can change the specificity from one enzyme class to another. LASK80

suggests that among KuDoms, inhibitors with P1=Lys or Arg inhibit trypsin, those with P1=Tyr, Phe, Trp, Leu and Met inhibit chymotrypsin, and those with P1=Ala or Ser are likely to inhibit elastase. Among the Kazal inhibitors, LASK80 continues, inhibitors with P1=Leu or Met are strong inhibitors of elastase, and in the Bowman-Kirk family elastase is inhibited with P1=Ala, but not with P1=Leu. Such limited changes do not provide inhibitors of truly high affinity (*i.e.* better than 1 to 10 nM).

KuDoms are defined above. The 3D structure (at high resolution) of BPTI (the archetypal Kunitz domain) is known. One of the X-ray structures is deposited in the Brookhaven Protein Data Bank as "6PTI"]. The 3D structure of some BPTI homologues (EIGE90, HYNE90) are known. At least seventy KuDom sequences are known. Known human homologues include three KuDoms of LACI (WUNT88, GIRA89, NOVO89), two KuDoms of Inter- α -Trypsin Inhibitor, APP-I (KIDO88), a KuDom from collagen, and three KuDoms of TFPI-2 (SPRE94).

LACI

Lipoprotein-associated coagulation inhibitor (LACI) is a human serum phosphoglycoprotein with a molecular weight of 39 kDa (amino-acid sequence in Table 1) containing three KuDoms. We refer hereinafter to the protein as LACI and to the Kunitz domains thereof as LACI-K1 (residues 50 to 107), LACI-K2 (residues 121 to 178), and LACI-K3 (213 to 270). The cDNA sequence of LACI is reported in WUNT88. GIRA89 reports mutational studies in which the P1 residues of each of the three KuDoms were altered. LACI-K1 inhibits Factor VIIa (F.VII_a) when F.VII_a is complexed to tissue factor and LACI-K2 inhibits Factor X_a. It is not known whether LACI-K3 inhibits anything. Neither LACI nor any of the KuDoms of LACI is a potent plasma kallikrein inhibitor.

In one preferred embodiment of this invention, KuDoms are substantially homologous with LACI-K1, but differ in ways that confer strong plasma kallikrein inhibitory activity discussed below. Other KuDoms of this invention are homologous to other naturally-occurring KuDoms, particularly to other human KuDoms. For use in humans, the proteins of this invention are designed to be highly similar in sequence to one or another human KuDom to reduce the risk of causing an immune response.

Variegation of a protein is typically achieved by preparing a correspondingly variegated mixture of DNA (with variable codons encoding variable residues), cloning it into suitable vectors, and expressing the DNA in suitable host cells. For any given protein molecule of the

library, the choice of amino acid at each variable residue, subject to the above constraints, is random, the result of the happenstance of which DNA expressed that protein molecule.

FIRST LACI-K1 LIBRARY SCREENED FOR pKA BINDING

Applicants have screened a first large library of LACI-K1 domains (patern of variegation is shown in Table 21), with the results shown in Table 3. In Table 3, "Library Residues" are those permitted to occur, randomly, at that position, in the library, and "Preferred Residues" are those appearing at that position in at least one of the 10 variants identified as binding to human kallikrein.

At residues 13, 16, 17, 18, 31, and 32, the selections are very strong. At position 34, the selection for either SER or THR is quite strong. At position 39, the selection for GLY is strong. Position 19 seems to be rather tolerant.

It should be appreciated that Applicants have not sequenced all of the positive isolates in this or other the libraries herein disclosed, that some of the possible mutant proteins may not have been present in the library in detectable amounts, and that, at some positions, only some of the possible amino acids were intended to be included in the library.

SECOND LIBRARY OF LACI-K1 and SELECTION OF NEW KALLIKREIN INHIBITORS

Applicants prepared a second LACI-K1 library as shown in Table 750. This library utilized the observation of the first selection and allows variability at positions 10, 11, 13, 15, 16, 17, 18, 19, and 21. The residues at positions 34 and 39 were fixed at S₃₄ and G₃₉. Selectants KK2/#1 through KK2/#13, as shown in Table 2 were obtained in the same manner as described in the Example section for the first screening. Applicants prepared the proteins KK2/#11 and KK2/#13 in *S. cerevisiae* in the Mat α system described herein. Preliminary measurements indicate that these proteins are very potent pKA inhibitors with K_i less than 300 pM and probably less than 100 pM.

Using the selected sequences and the binding data of selected KuDoms, we can write a recipe for a high-affinity pKA-inhibiting KuDom that can be applied to other human KuDom parentals. First, the KuDom must meet the requirements in Table 14. The substitutions shown in Table 15 are likely to confer high-affinity pKA inhibitory activity on any KuDom. Thus a protein that contains a sequence that is a KuDom, as shown in Table 14, and that contains at each of the position 12-21 and 32-39 an amino-acid type shown in Table 15 for that position is likely

to be a potent inhibitor of human pKA. More preferably, the protein would have an amino-acid type shown in Table 15 for all of the positions listed in Table 15. To reduce the potential for immune response, one should use one or another human KuDom as parental protein to give the sequence outside the binding region.

5 It is likely that a protein that comprises an amino-acid sequence that is substantially homologous to one of KK2/#13, KK2/#11, or KKII/3#6 from residue 5 through residue 55 (as shown in Table 2) and is identical to one of KK2/#13, KK2/#11, or KKII/3#6 at positions 13-19, 31, 32, 34, and 39 will inhibit human pKA with a K_i of 5 nM or less. KK2/#13, KK2/#11, and KKII/3#6 differs from LACI-K1 at 10, 8, and 7 positions respectively. It is not clear that these
10 substitutions are equally important in fostering pKA binding and inhibition. From the known pKA inhibitors listed, one can prepare a series of molecules that are progressively reverted toward LACI-K1. It is expected that the molecules will show less affinity for pKA but also less potential for antigenicity. A person skilled in the art can pick a protein of sufficient potency and low immunogenicity from this collection. It is also possible that substitutions in one of the listed pKA
15 inhibitors by amino acids that differ from LACI-K1 can reduce the immunogenicity without reducing the affinity for pKA to a degree that makes the protein unsuitable for use as a drug.

DESIGNED KuDom PKA Inhibitors

Hereinafter, "DKI" will mean a "Designed PKA Inhibitor" that are KuDoms that incorporate amino-acid sequence information from the SPI series of molecules, especially KK2/#13, KK2/#11,
20 or KKII/3#6. Sequences of several DKIs and their parental proteins are given in Table 2. Hereinafter, the statement "the mutations XnnY₁, XnnY₂, ... may not be needed" means that each of the mutations might be separately found to be unnecessary. That is, the list is not to be taken as a block to be applied together, but as a list of things to be tested. Similarly, the lists of additional mutations are to be tested singly.

25 Protein DKI-1.2.1 is based on human LACI-K2 and shown in Table 2. The mutations P11G, I13R, Y17A, I18H, T19P, Y21W, R32E, K34S, and L39G are likely to confer high affinity for pKA. Some of these substitutions may not be necessary; in particular, P11G and T19P may not be necessary. Other mutations that might improve the pKA affinity include E9A, D10E, G16A, Y21F, and L39E.

30 Protein DKI-1.3.1 (Table 2) is based on human LACI-K3. The mutations R11D, L13P, N17A, E18H, N19P, R31E, K34S, and S36G are intended to confer high affinity for pKA. Some

of these substitutions may not be necessary; in particular, N19P may not be necessary. Other changes that might improve K_D include D10E, F21W and G39E.

Protein DKI-2.1 (Table 2) is based on the **human collagen $\alpha 3$ KuDom**. The mutations D16A, F17A, I18H, R32E, and W34S are likely to confer high affinity for pKA. Some of these substitutions may not be necessary; in particular, R32E may not be necessary. Other mutations that might improve the pKA affinity include K9A, D10E, D16G, K20R, R32T, W34V, and G39E.

DKI-3.1.1 (Table 2) is derived from **Human TFPI-2 domain 1**. The exchanges Y11G, L17A, L18H, R31E, and L34S are likely to confer high affinity for pKA. The mutation L34S may not be needed. Other mutations that might foster pKA binding include Y21W, Y21F, Q32E, L34T, L34I, and E39G.

DKI-3.2.1 (Table 2) is derived from **Human TFPI-2 domain 2**. This parental domain contains insertions after residue 9 (one residue) and 42 (two residues). The mutations E15R, G16A, S17A, T18H, E19P, K32T, and F34V are intended to confer affinity for pKA. If one needs a pKA inhibitor based on TFPI domain 2, a preferred route is to make a library of domains allowing the substitutions given and many others and then select binders.

DKI-3.3.1 (Table 2) is derived from **human TFPI-2, domain 3**. The substitutions L13H, S15R, and N17A are likely to confer high affinity for pKA. Other mutations that might foster pKA binding include D10E, T19Q, Y21W, T36G, and G39E.

DKI-4.1.1 (Table 2) is from **human ITI-K1** by assertion of S10D, M15R, M17A, T18H, Q34S, and M39G. The mutations M39G and Q34V may not be necessary. Other mutations that should foster pKA binding include: G16A, M17N, S19Q, Y21W, and Y21F.

DKI-4.2.1 (Table 2) is from **human ITI-K2** through the mutations V10D, R11D, F17A, I18H, V31E, L32E, P34S, and Q39E. The mutations V31E, L32E, and Q39E might not be necessary. Other mutation that should foster pKA binding include: V10E, Q19P, L20R, W21F, P34I, and Q39G. DKI-4.2.2 has eight mutations: V10D, R11D, F17A, I18H, L20R, V31E, L32E, and P34S.

DKI-5.1 is derived from human APP-I (also known as Protease Nexin-II) by mutations M17A, I18H, S19P, A31E, and P32E and is likely to be a potent pKA inhibitor. The mutations S19P, A31E, and P32E may not be needed. Other mutations that might foster pKA binding include T11D.

DKI-6.1 is derived from the **HKI B9 KuDom (NORR93)** by the five substitutions: K11D,

Q15R, T16A, M17A, M18H, T19P, and L32E. DKI-6.1 is likely to be a potent pKA inhibitor. The mutations L32E, and T19P might not be needed.

Although BPTI is not an especially good pKA inhibitor, it could be made into one. DKI-7.1 is derived from BPTI by the mutations Y10E, K15R, R17A, R18H, I19P, Q31E, T32E, and R39E which is likely to increase the affinity for pKA. The mutations Y10E, K15R, I19P, Q31E, T32E, and R39E may not be needed; the really important mutations are R17A and R18H.

MODIFICATION OF KUNITZ DOMAINS

KuDoms are quite small; if this should cause a pharmacological problem, such as excessively quick elimination from circulation, two or more such domains may be joined. A preferred linker is a sequence of one or more amino acids. A preferred linker is one found between repeated domains of a human protein, especially the linkers found in human BPTI homologues, one of which has two domains (BALD85, ALBR83a, ALBR83b) and another of which has three (WUNT88). Peptide linkers have the advantage that the entire protein may then be expressed by recombinant DNA techniques. It is also possible to use a nonpeptidyl linker, such as one of those commonly used to form immunogenic conjugates. An alternative means of increasing the serum residence of a BPTI-like KuDom is to link it to polyethyleneglycol, so called PEGylation (DAVI79).

WAYS TO IMPROVE SPECIFICITY OF, FOR EXAMPLE, KKII/3#7, KK2/#11, AND KK2/#13 FOR PLASMA KALLIKREIN:

Because we have made a large part of the surface of KKII/3#6, KK2/#11, and KK2/#13 complementary to the surface of pKA, R₁, is not essential for specific binding to pKA. Many of the enzymes in the clotting and fibrinolytic pathways cut preferentially after Arg or Lys. Not having a basic residue at the P1 position may give rise to greater specificity. The variant KKII/3#7-K15A (shown in Table 27), having an ALA at P1, is likely to be a good pKA inhibitor and may have higher specificity for pKA relative to other proteases than does KKII/3#7. The affinity of KKII/3#7-K15A for pKA is likely to be less than the affinity of KKII/3#7 for pKA, but the loss of affinity for other Arg/Lys-preferring enzymes is likely to be greater and, in many applications, specificity is more important than affinity. Other mutants that are likely to have good affinity and very high specificity include KK2/#13-R15A and KK2/#11-R15S. This approach could be applied to other high-affinity pKA inhibitors.

MODE OF PRODUCTION

The proteins of this invention may be produced by any conventional technique, including

- (a) nonbiological synthesis by sequential coupling of component amino acids,
- 5 (b) production by recombinant DNA techniques in a suitable host cell, and
- (c) removal of undesired sequences from LACI and coupling of synthetic replacement sequences

The proteins disclosed herein are preferably produced, recombinantly, in a suitable host, such as
10 bacteria from the genera *Bacillus*, *Escherichia*, *Salmonella*, *Erwinia*, and yeasts from the genera *Hansenula*, *Kluyveromyces*, *Pichia*, *Rhinosporidium*, *Saccharomyces*, and *Schizosaccharomyces*, or cultured mammalian cells such as COS-1. The more preferred hosts are microorganisms of the species *Pichia pastoris*, *Bacillus subtilis*, *Bacillus brevis*, *Saccharomyces cerevisiae*, *Escherichia coli* and *Yarrowia lipolytica*. Any promoter, regulatable or constitutive, which is functional in
15 the host may be used to control gene expression.

Preferably the proteins are secreted. Most preferably, the proteins are obtained from conditioned medium. It is not required that the proteins described herein be secreted. Secretion is the preferred route because proteins are more likely to fold correctly, can be produced in conditioned medium with few contaminants, and are less likely to be toxic to host cells. Secretion
20 is not required.

Unless there is a specific reason to include glycoproteins, we prefer proteins designed to lack N-linked glycosylation sites to reduce potential for antigenicity of glycoproteins and so that equivalent proteins can be expressed in a wide variety of organisms including: 1) *E. coli*, 2) *B. subtilis*, 3) *P. pastoris*, 4) *S. cerevisiae*, and 5) mammalian cells.

25 Several means exist for reducing the problem of host cells producing proteases that degrade the recombinant product; see, *inter alia* BANE90 and BANE91. VAND92 reports that overexpression of the *B. subtilis* signal peptidase in *E. coli* leads to increased expression of a heterologous fusion protein. ANBA88 reports that addition of PMSF (a serine proteases inhibitor) to the culture medium improved the yield of a fusion protein.

30 Other factors that may affect production of these and other proteins disclosed herein include: 1) codon usage (optimizing codons for the host is preferred), 2) signal sequence, 3) amino-acid sequence at intended processing sites, presence and localization of processing

enzymes, deletion, mutation, or inhibition of various enzymes that might alter or degrade the engineered product and mutations that make the host more permissive in secretion (permissive secretion hosts are preferred).

Reference works on the general principles of recombinant DNA technology include

5 Watson *et al.*, **Molecular Biology of the Gene**, Volumes I and II, The Benjamin/Cummings Publishing Company, Inc., Menlo Park, CA (1987); Darnell *et al.*, **Molecular Cell Biology**, Scientific American Books, Inc., New York, N.Y. (1986); Lewin, **Genes II**, John Wiley & Sons, New York, N.Y. (1985); Old, *et al.*, **Principles of Gene Manipulation: An Introduction to Genetic Engineering**, 2d edition, University of California Press, Berkeley, CA (1981); Sambrook

10 *et al.*, **Molecular Cloning: A Laboratory Manual**, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989); and Ausubel *et al.*, **Current Protocols in Molecular Biology**, Wiley Interscience, NY, (1987, 1992). These references are herein entirely incorporated by reference as are the references cited therein.

PREPARATION OF PEPTIDES

15 Chemical polypeptide synthesis is a rapidly evolving area in the art, and methods of solid phase polypeptide synthesis are well-described in the following references, hereby entirely incorporated by reference: (Merrifield, *J Amer Chem Soc* 85:2149-2154 (1963); Merrifield, *Science* 232:341-347 (1986); Wade *et al.*, *Biopolymers* 25:S21-S37 (1986); Fields, *Int J Polypeptide Prot Res* 35:161 (1990); MilliGen Report Nos. 2 and 2a, Millipore Corporation, Bedford, MA,

20 1987) Ausubel *et al.*, *supra*, and Sambrook *et al.*, *supra*. Tan and Kaiser (*Biochemistry*, 1977, 16:1531-41) synthesized BPTI and a homologue eighteen years ago.

As is known in the art, such methods involve blocking or protecting reactive functional groups, such as free amino, carboxyl and thio groups. After polypeptide bond formation, the protective groups are removed. Thus, the addition of each amino acid residue requires several

25 reaction steps for protecting and deprotecting. Current methods utilize solid phase synthesis, wherein the C-terminal amino acid is covalently linked to an insoluble resin particles that can be filtered. Reactants are removed by washing the resin particles with appropriate solvents using an automated machine. Various methods, including the "tBoc" method and the "Fmoc" method are well known in the art. See, *inter alia*, Atherton *et al.*, *J Chem Soc Perkin Trans* 1:538-546

30 (1981) and Sheppard *et al.*, *Int J Polypeptide Prot Res* 20:451-454 (1982).

ASSAYS FOR PLASMA KALLIKREIN BINDING AND INHIBITION

Any suitable method may be used to test the compounds of this invention. Scatchard (*Ann NY*

Acad Sci (1949) 51:660-669) described a classical method of measuring and analyzing binding which is applicable to protein binding. This method requires relatively pure protein and the ability to distinguish bound protein from unbound.

A second appropriate method of measuring K_D is to measure the inhibitory activity against the enzyme. If the K_D to be measured is in the 1 nM to 1 μ M range, this method requires chromogenic or fluorogenic substrates and tens of micrograms to milligrams of relatively pure inhibitor. For the proteins of this invention, having K_D in the range 5 nM to 50 pM, nanograms to micrograms of inhibitor suffice. When using this method, the competition between the inhibitor and the enzyme substrate can give a measured K_i that is higher than the true K_i . Measurement reported here are not so corrected because the correction would be very small and the any correction would reduce the K_i . Here, we use the measured K_i as a direct measure of K_D .

A third method of determining the affinity of a protein for a second material is to have the protein displayed on a genetic package, such as M13, and measure the ability of the protein to adhere to the immobilized "second material". This method is highly sensitive because the genetic packages can be amplified. We obtain at least semiquantitative values for the binding constants by use of a pH step gradient. Inhibitors of known affinity for the protease are used to establish standard profiles against which other phage-displayed inhibitors are judged. Any other suitable method of measuring protein binding may be used.

Preferably, the proteins of this invention have a K_D for pKA of at most about 5nM, more preferably at most about 300 pM, and most preferably 100 pM or less. Preferably, the binding is inhibitory so that K_i is the same as K_D . The K_i of KKII/3#6 is about 300 pM and the K_i s of KK2/#11 and KK2/#13 are less than 300 pM and probably less than 100 pM.

PHARMACEUTICAL METHODS AND PREPARATIONS

The preferred subject of this invention is a mammal. The invention is particularly useful in the treatment of humans, but is suitable for veterinary applications too.

Herein, "protection" includes "prevention", "suppression", and "treatment". "Prevention" involves administration of drug prior to the induction of disease. "Suppression" involves administration of drug prior to the clinical appearance of disease. "Treatment" involves administration of drug after the appearance of disease.

In human and veterinary medicine, it may not be possible to distinguish between "preventing" and "suppressing" since the inductive event(s) may be unknown or latent, or the patient is not ascertained until after the occurrence of the inductive event(s). We use the term

"prophylaxis" as distinct from "treatment" to encompass "preventing" and "suppressing". Herein, "protection" includes "prophylaxis". Protection need not be absolute to be useful.

Proteins of this invention may be administered, by any means, systemically or topically, to protect a subject against a disease or adverse condition. For example, administration of such a composition may be by any parenteral route, by bolus injection or by gradual perfusion. Alternatively, or concurrently, administration may be by the oral route. A suitable regimen comprises administration of an effective amount of the protein, administered as a single dose or as several doses over a period of hours, days, months, or years.

The suitable dosage of a protein of this invention may depend on the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the desired effect. However, the most preferred dosage can be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue experimentation by adjustment of the dose in ways known in the art.

For methods of preclinical and clinical testing of drugs, including proteins, see, e.g., Berkow *et al.*, eds., **The Merck Manual**, 15th edition, Merck and Co., Rahway, N.J., 1987; Goodman *et al.*, eds., **Goodman and Gilman's The Pharmacological Basis of Therapeutics**, 8th edition, Pergamon Press, Inc., Elmsford, N.Y., (1990); **Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics**, 3rd edition, ADIS Press, LTD., Williams and Wilkins, Baltimore, MD. (1987), Ebadi, **Pharmacology**, Little, Brown and Co., Boston, (1985), which references and references cited there are hereby incorporated by reference.

In addition to a protein here disclosed, a pharmaceutical composition may contain pharmaceutically acceptable carriers, excipients, or auxiliaries. See, e.g., Berker, *supra*, Goodman, *supra*, Avery, *supra* and Ebadi, *supra*.

IN VITRO DIAGNOSTIC METHODS AND REAGENTS

Proteins of this invention may be applied *in vitro* to any suitable sample that might contain plasma kallikrein to measure the pKA present. To do so, the assay must include a Signal Producing System (SPS) providing a detectable signal that depends on the amount of pKA present. The signal may be detected visually or instrumentally. Possible signals include production of colored, fluorescent, or luminescent products, alteration of the characteristics of absorption or emission of radiation by an assay component or product, and precipitation or agglutination of a component or product.

The component of the SPS most intimately associated with the diagnostic reagent is called

the "label". A label may be, *e.g.*, a radioisotope, a fluorophore, an enzyme, a co-enzyme, an enzyme substrate, an electron-dense compound, or an agglutinable particle. A radioactive isotope can be detected by use of, for example, a γ counter or a scintillation counter or by autoradiography. Isotopes which are particularly useful are ^3H , ^{125}I , ^{131}I , ^{35}S , ^{14}C , and, preferably, ^{125}I . It is also possible to label a compound with a fluorescent compound. When the fluorescently labeled compound is exposed to light of the proper wave length, its presence can be detected. Among the most commonly used fluorescent labelling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, *o*-phthaldehyde, and fluorescamine. Alternatively, fluorescence-emitting metals, such as ^{125}Eu or other lanthanide, may be attached to the binding protein using such metal chelating groups as diethylenetriaminepentaacetic acid or ethylenediamine-tetraacetic acid. The proteins also can be detectably labeled by coupling to a chemiluminescent compound, such as luminol, isolumino, therromatic acridinium ester, imidazole, acridinium salt, and oxalate ester. Likewise, a bioluminescent compound, such as luciferin, luciferase and aequorin, may be used to label the binding protein. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Enzyme labels, such as horseradish peroxidase and alkaline phosphatase, are preferred.

There are two basic types of assays: heterogeneous and homogeneous. In heterogeneous assays, binding of the affinity molecule to analyte **does not** affect the label; thus, to determine the amount of analyte, bound label must be separated from free label. In homogeneous assays, the interaction **does** affect the activity of the label, and analyte can be measured without separation.

In general, a kallikrein-binding protein (KBP) may be used diagnostically in the same way that an anti-pKA antibody is used. Thus, depending on the assay format, it may be used to assay pKA, or, by competitive inhibition, other substances which bind pKA.

The sample will normally be a biological fluid, such as blood, urine, lymph, semen, milk, or cerebrospinal fluid, or a derivative thereof, or a biological tissue, *e.g.*, a tissue section or homogenate. The sample could be anything. If the sample is a biological fluid or tissue, it may be taken from a human or other mammal, vertebrate or animal, or from a plant. The preferred sample is blood, or a fraction or derivative thereof.

In one embodiment, the pKA-binding protein (KBP) is immobilized, and pKA in the sample is allowed to compete with a known quantity of a labeled or specifically labelable pKA analogue. The "pKA analogue" is a molecule capable of competing with pKA for binding to the KBP, which includes pKA itself. It may be labeled already, or it may be labeled subsequently by

specifically binding the label to a moiety differentiating the pKA analogue from pKA. The phases are separated, and the labeled pKA analogue in one phase is quantified.

In a "sandwich assay", both an insolubilized pKA-binding agent (KBA), and a labeled KBA are employed. The pKA analyte is captured by the insolubilized KBA and is tagged by the labeled KBA, forming a tertiary complex. The reagents may be added to the sample in any order. The KBAs may be the same or different, and only one KBA need be a KBP according to this invention (the other may be, *e.g.*, an antibody). The amount of labeled KBA in the tertiary complex is directly proportional to the amount of pKA in the sample.

The two embodiments described above are both heterogeneous assays. A homogeneous assay requires only that the label be affected by the binding of the KBP to pKA. The pKA analyte may act as its own label if a pKA inhibitor is used as a diagnostic reagent.

A label may be conjugated, directly or indirectly (*e.g.*, through a labeled anti-KBP antibody), covalently (*e.g.*, with SPDP) or noncovalently, to the pKA-binding protein, to produce a diagnostic reagent. Similarly, the pKA binding protein may be conjugated to a solid phase support to form a solid phase ("capture") diagnostic reagent. Suitable supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, and magnetite. The carrier can be soluble to some extent or insoluble for the purposes of this invention. The support material may have any structure so long as the coupled molecule is capable of binding pKA.

IN VIVO DIAGNOSTIC USES

A Kunitz domain that binds very tightly to pKA can be used for *in vivo* imaging. Diagnostic imaging of disease foci was considered one of the largest commercial opportunities for monoclonal antibodies, but this opportunity has not been achieved. Despite considerable effort, only two monoclonal antibody-based imaging agents have been approved. The disappointing results obtained with monoclonal antibodies is due in large measure to:

- i) Inadequate affinity and/or specificity;
- ii) Poor penetration to target sites;
- iii) Slow clearance from nontarget sites;
- iv) Immunogenicity (most are murine); and
- v) High production cost and poor stability.

These limitations have led most in the diagnostic imaging field to begin to develop peptide-based imaging agents. While potentially solving the problems of poor penetration and slow clearance, peptide-based imaging agents are unlikely to possess adequate affinity, specificity and *in vivo*

stability to be useful in most applications.

Engineered proteins are uniquely suited to the requirements for an imaging agent. In particular the extraordinary affinity and specificity that is obtainable by engineering small, stable, human-origin protein domains having known *in vivo* clearance rates and mechanisms combine to provide earlier, more reliable results, less toxicity/side effects, lower production and storage cost, and greater convenience of label preparation. Indeed, it should be possible to achieve the goal of realtime imaging with engineered protein imaging agents. Thus, a Kallikrein-binding protein, e.g., KKII/3#6, KK2/#11, and KK2/#13 may be used for localizing sites of excessive pKA activity.

Radio-labelled binding protein may be administered to the human or animal subject. Administration is typically by injection, e.g., intravenous or arterial or other means of administration in a quantity sufficient to permit subsequent dynamic and/or static imaging using suitable radio-detecting devices. The dosage is the smallest amount capable of providing a diagnostically effective image, and may be determined by means conventional in the art, using known radio-imaging agents as guides.

Typically, the imaging is carried out on the whole body of the subject, or on that portion of the body or organ relevant to the condition or disease under study. The radio-labelled binding protein has accumulated. The amount of radio-labelled binding protein accumulated at a given point in time in relevant target organs can then be quantified.

A particularly suitable radio-detecting device is a scintillation camera, such as a γ camera. The detection device in the camera senses and records (and optional digitizes) the radioactive decay. Digitized information can be analyzed in any suitable way, many of which are known in the art. For example, a time-activity analysis can illustrate uptake through clearance of the radio-labelled binding protein by the target organs with time.

Various factors are taken into consideration in picking an appropriate radioisotope. The isotope is picked: to allow good quality resolution upon imaging, to be safe for diagnostic use in humans and animals, and, preferably, to have a short half-life so as to decrease the amount of radiation received by the body. The radioisotope used should preferably be pharmacologically inert, and the quantities administered should not have substantial physiological effect. The binding protein may be radio-labelled with different isotopes of iodine, for example ^{123}I , ^{125}I , or ^{131}I (see, for example, U.S. Patent 4,609,725). The amount of labeling must be suitably monitored.

In applications to human subjects, it may be desirable to use radioisotopes other than ^{125}I

for labelling to decrease the total dosimetry exposure of the body and to optimize the detectability of the labelled molecule. Considering ready clinical availability for use in humans, preferred radio-labels include: ^{99m}Tc , ^{67}Ga , ^{68}Ga , ^{90}Y , ^{111}In , ^{113m}In , ^{123}I , ^{186}Re , ^{188}Re or ^{211}At . Radio-labelled protein may be prepared by various methods. These include radio-halogenation by the chloramine-T or lactoperoxidase method and subsequent purification by high pressure liquid chromatography, for example, see Gutkowska *et al* in "Endocrinology and Metabolism Clinics of America: (1987) 16 (1):183. Other methods of radio-labelling can be used, such as IODOBEADS™.

A radio-labelled protein may be administered by any means that enables the active agent to reach the agent's site of action in a mammal. Because proteins are subject to digestion when administered orally, parenteral administration, *i.e.*, intravenous subcutaneous, intramuscular, would ordinarily be used to optimize absorption.

High-affinity, high-specificity inhibitors are also useful for *in vitro* diagnostics of excess human pKA activity.

Other Uses

The kallikrein-binding proteins of this invention may also be used to purify kallikrein from a fluid, *e.g.*, blood. For this, the KBP is preferably immobilized on a support. Such supports, include those already mentioned as useful in preparing solid phase diagnostic reagents.

Proteins can be used as molecular weight markers for reference in the separation or purification of proteins. Proteins may need to be denatured to serve as molecular weight markers.

A second general utility for proteins is the use of hydrolyzed protein as a nutrient source. Proteins may also be used to increase the viscosity of a solution.

The proteins of this invention may be used for any of the foregoing purposes, as well as for therapeutic and diagnostic purposes as discussed further earlier in this specification.

EXAMPLE 1: CONSTRUCTION OF FIRST LACI-K1 LIBRARY

A synthetic oligonucleotide duplex having *Nsi*I- and *Mlu*I-compatible ends was cloned into a parental vector (LACI:III) previously cleaved with the above two enzymes. The resultant ligated material was transfected by electroporation into XLIMR (F) *Escherichia coli* strain and plated on Amp plates to obtain phage-generating Ap^{R} colonies. The variegation scheme for Phase 1 focuses on the P1 region, and affected residues 13, 16, 17, 18 and 19. It allowed for 6.6×10^5 different DNA sequences (3.1×10^5 different protein sequences). The library obtained consisted of 1.4×10^6 independent cfu's which is approximately a two fold representation of the whole

library. The phage stock generated from this plating gave a total titer of 1.4×10^{13} pfu's in about 3.9 ml, with each independent clone being represented, on average, 1×10^7 in total and 2.6×10^6 times per ml of phage stock.

To allow for variegation of residues 31, 32, 34 and 39 (phase II), synthetic oligonucleotide duplexes with *Mlu*I- and *Bst*EII- compatible ends were cloned into previously cleaved R_f DNA derived from one of the following

- i) the parental construction,
- ii) the phase I library, or
- iii) display phage selected from the first phase binding to a given target.

- 10 The variegation scheme for phase II allows for 4096 different DNA sequences (1600 different protein sequences) due to alterations at residues 31, 32, 34 and 39. The final phase II variegation is dependent upon the level of variegation remaining following the three rounds of binding and elution with a given target in phase I.

- 15 The combined possible variegation for both phases equals 2.7×10^8 different DNA sequences or 5.0×10^7 different protein sequences. When previously selected display phage are used as the origin of R_f DNA for the phase II variegation, the final level of variegation is probably in the range of 10^5 to 10^6 .

Example 2: Screening of LACI (K1) Library for Binding to Kallikrein

- 20 The overall scheme for selecting a LACI-K1 variant to bind to a given protease involves incubation of the phage-display library with the kallikrein-beads of interest in a buffered solution (PBS containing 1 mg/ml BSA) followed by washing away the unbound and poorly retained display-phage variant with PBS containing 0.1% Tween 20. Kallikrein beads were made by coupling human plasma Kallikrein (Calbiochem, San Diego, CA, # 420302) to agarose beads using Reactigel (6x) (Pierce, Rockford, IL, #202606). The more strongly bound display-phage are
- 25 eluted with a low pH elution buffer, typically citrate buffer (pH 2.0) containing 1 mg/ml BSA, which is immediately neutralized with Tris buffer to pH 7.5. This process constitutes a single round of selection.

The neutralized eluted display-phage can be either used:

- i) to inoculate an F^+ strain of *E. coli* to generate a new display-phage stock, to be used for subsequent rounds of selection (so-called conventional screening), or
- 30 ii) be used directly for another immediate round of selection with the protease beads (so-called quick screening).

Typically, three rounds of either method, or a combination of the two, are performed to give rise to the final selected display-phage from which a representative number are sequenced and analyzed for binding properties either as pools of display-phage or as individual clones.

Two phases of selection were performed, each consisting of three rounds of binding and elution. Phase I selection used the phase I library (variegated residues 13, 16, 17, 18, and 19) which went through three rounds of binding and elution against a target protease giving rise to a subpopulation of clones. The R₁ DNA derived from this selected subpopulation was used to generate the Phase II library (addition of variegated residues 31, 32, 34 and 39). The 1.8×10^7 independent transformants were obtained for each of the phase II libraries. The phase II libraries underwent three further rounds of binding and elution with the same target protease giving rise to the final selectants.

Following two phases of selection against human plasma kallikrein-agarose beads a number (10) of the final selection display-phage were sequenced. The amino-acid sequences are shown in Table 2, entries KBPcon1 through KKII/3#C.

Table 23 shows that KkII/3(D) is a highly specific inhibitor of human Kallikrein. Phage that display the LACI-K1 derivative KkII/3(D) bind to Kallikrein beads at least 50-times more than it binds to other protease targets.

Preliminary measurements indicate that KKII/3#6 is a potent inhibitor of pKA with K_i probably less than 500 pM.

EXPRESSION, PURIFICATION AND KINETIC ANALYSIS.

The three isolates KKII/3#6, KK2/#11, and KK2/#13 were recloned into a yeast expression vector. The yeast expression vector is derived from pMFalpha8 (KURJ82 and MIYA85). The LACI variant genes were fused to part of the mat α 1 gene, generating a hybrid gene consisting of the mat α 1 promoter-signal peptide and leader sequence-fused to the LACI variant. The cloning site is shown in Table 24. Note that the correctly processed LACI-K1 variant protein should be as detailed in Table 2 with the addition of residues glu-ala-ala-glu to the N-terminal met (residue 1 in Table 2). Expression in *S. cerevisiae* gave acceptable yield typical of this system. Yeast-expressed LACI (kunitz domain 1), BPTI and LACI variants: KKII/3#6, KK2/#11, and KK2/#13 were purified by affinity chromatography using trypsin-agarose beads.

For larger-scale production, *Pichia pastoris* is a preferred host. The most preferred production system in *P. pastoris* is the alcohol oxidase system. Others have produced a number

of proteins in the yeast *Pichia pastoris*. For example, Vedvick *et al.* (VEDV91) and Wagner *et al.* (WAGN92) produced aprotinin from the alcohol oxidase promoter with induction by methanol as a secreted protein in the culture medium at ≈ 1 mg/ml. Gregg *et al.* (GREG93) have reviewed production of a number of proteins in *P. pastoris*. Table 1 of GREG93 shows proteins that have
5 been produced in *P. pastoris* and the yields.

All references, including those to U.S. and foreign patents or patent applications, and to nonpatent disclosures, are hereby incorporated by reference in their entirety.

TABLE 1: Sequence of whole LACI:

1 5 5 5 5 5
 1 MIYTMKKVHA LWASVCLLLN LAPAPLNAds eedehtiit dtelpplklm
 5 51 HSFCAFKADD GPCKAIMKRF FFNIFTRQCE EFIYGGCEGN QNRFESLEEC
 101 KKMCTRDnan riikttlqge kpdfcfleed pgicrgyitr yfynnqtkgc
 151 erfkyggclg nmnnfetlee cknicedgpn gfqvdnygtq lnavnsltp
 201 qstkvp^slfe fhg^pswcltp adrglcrane nrfyynsvig kcrpfkysgc
 251 **ggnennftsk** **qeclrackkg** fiqriskggl iktkrkrkkq rvkiayeeif
 10 301 vknm (SEQ ID NO. 18)

The signal sequence (1-28) is uppercase and underscored

LACI-K1 is uppercase

LACI-K2 is underscored

LACI-K3 is bold

TABLE 2 is below.

Table 3: Summary of first selection of LACI-K1 domains for binding to pKA.

BPTI #	(Lac I)	Library Residues	Preferred Residues
13	P	LHPR	HP
16	A	AG	AG
17	I	FYLHINA SCPRTVD G	NSA
18	M	all	HL
19	K	LWQMKAG SPRTVE	QLP
31	E	EQ	E
32	E	EQ	EQ
34	I	all	STI
39	E	all	GEA

Table 2: Sequences of Kunitz domains, some of which inhibit human pKA.

	Amino-acid sequence	
Ident	11111111122222222222222222222222 12345678901234567890123456789012345678901234567890123456789012345678	SEQ ID NO.
BPTI	RPFDCLEPPYTGPCAKRIIRYFYNAKAGLCQTFVYGCGRAKRNNFKSAEDCMRTCGGA	SEQ ID NO. 2
LACI-K1	mhsfcakaddgpckaimkrfffniftrqceefiyggcegnqrfsleeckkmctrd	SEQ ID NO. 3
KBPconl	mhsfcakaddgHckaANHQRfffniftrqCEEfSyggcGgnqnrfesleeckkmctrd	SEQ ID NO. 4
KKII/3#1	mhsfcakaddgHckASLPrfffniftrqCEEfIyggcEgnqnrfesleeckkmctrd	SEQ ID NO. 5
KKII/3#2	mhsfcakaddgPckANHLrfffniftrqCEEfSyggcGgnqnrfesleeckkmctrd	SEQ ID NO. 6
KKII/3#3	mhsfcakaddgHckANHQRfffniftrqCEEfTyggcGgnqnrfesleeckkmctrd	SEQ ID NO. 7
KKII/3#4	mhsfcakaddgHckANHQRfffniftrqCEQfTyggcAgnqnrfesleeckkmctrd	SEQ ID NO. 8
KKII/3#5	mhsfcakaddgHckASLPrfffniftrqCEEfIyggcGgnqnrfesleeckkmctrd	SEQ ID NO. 9
KKII/3#6	mhsfcakaddgHckANHQRfffniftrqCEEfSyggcGgnqnrfesleeckkmctrd	SEQ ID NO. 10
KKII/3#7	mhsfcakaddgHckANHQRfffniftrqCEEfSyggcGgnqnrfesleeckkmctrd	SEQ ID NO. 11
KKII/3#8	mhsfcakaddgHckANHQRfffniftrqCEEfSyggcGgnqnrfesleeckkmctrd	SEQ ID NO. 12
KKII/3#9	mhsfcakaddgHckANHQRfffniftrqCEEfSyggcGgnqnrfesleeckkmctrd	SEQ ID NO. 13
KKII/3#10	mhsfcakaddgHckGAHLrfffniftrqCEEfIyggcEgnqnrfesleeckkmctrd	SEQ ID NO. 14
KKI/3(a)	mhsfcakaddgRckGAHLrfffniftrqceefiyggcegnqrfsleeckkmctrd	SEQ ID NO. 15

Table 2: Sequences of Kunitz domains, some of which inhibit human pKA.

Ident	Amino-acid sequence	SEQ ID NO.
	111111111122222222223333333333444444444455555555	SEQ ID NO. 16
KK1/3(b)	mhsfcakaddgPckAIHLrfffniftrqceefiyggcegnqnrlesleackkmctrd	SEQ ID NO. 17
KK2/3#C	mhsfcakaddgHckANHQRfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 19
KK2/#13	mhsfcakadGgRcRGAHPrWfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 20
KK2/#14	mhsfcakadGgRcRGAHPrWfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 21
KK2/#5	mhsfcakadDgPCRAAHPrWfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 22
KK2/#11	mhsfcakadDgPCRAAHPrWfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 23
KK2/#1	mhsfcakadVgRcRGAHPrWfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 24
KK2/#4	mhsfcakadVgRcRGAQPrFfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 25
KK2/#6	mhsfcakadDgScRAAHLrWfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 26
KK2/#10	mhsfcakadEGgScRAAHQRWfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 27
KK2/#8	mhsfcakadDgPCRGALrFfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 28
KK2/#3	mhsfcakadDgHcRGALPrWfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 29
KK2/#9	mhsfcakadSgNcRGNLPrFfffniftrqceefSyggcGgnqnrlesleackkmctrd	SEQ ID NO. 30
KK2/#7	mhsfcakadSgRcRGNHQRfffniftrqceefSyggcGgnqnrlesleackkmctrd	

Table 2: Sequences of Kunitz domains, some of which inhibit human pKA.		
Ident	Amino-acid sequence	SEQ ID NO.
DKI-3.2.1	vpkvcrlqvs- vddqcRAAHPkyffnlssmtceEffsggchnr- ienrfpdeatcmgfcapk	SEQ ID NO. 42
TFPI-2 DOMAIN 3	IPSFYCYSKDEGLCSANVTRYFNPRTCDAFYTGCGNDNNFVSREDCKRACAKA	SEQ ID NO. 43
DKI-3.3.1	ipsfcyspkdegHcRaAHQryyfnpryrtcdafytgcgndnnfvsredckracaka	SEQ ID NO. 44
HUMAN ITI-K1	KEDSCQLGYSAGPCMGTSTRFYNGTSMACETFYGGCMGNGNFFVTEKECLQTCRTV	SEQ ID NO. 45
DKI-4.1.1	kedscqlgyDagpcRgAHPryfyngtmacetfSyggcGgngnnfvtেকেqlqtcrtv	SEQ ID NO. 46
Human ITI-K2	TVAACNLPIVRGPCRAFIQLWAFDAVKGKCVLFPYGGCQGNKNFYSEKECREYCGVP	SEQ ID NO. 47
DKI-4.2.1	tvaacnlpIDDgpcraAHqlwafdavkgkEEfSyggcEgngnkfyseকেcreycgvp	SEQ ID NO. 48
DKI-4.2.2	tvaacnlpIDDgpcraAHqRwafdavkgkEEfSyggcggngnkfyseকেcreycgvp	SEQ ID NO. 49
HUMAN PROTEASE NEXIN-II	VREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSA	SEQ ID NO. 50
DKI-5.1	vrevcseqaetgpcraAHPrwyfdvtegkEEfSyggcgggnrnnfdteeycmavcgsga	SEQ ID NO. 51
HKI B9 domain	LPNVCAFPMEKGPCQTYMTRWFFNFETGECELFAYGGCGGNSNNFLRKEKCEKCFCKFT	SEQ ID NO. 53
DKI-6.1	lpnvcafpmeDgpcRAAHPrwfnfsetgeceEfayggcggnnsnnflrকেকেckfckft	SEQ ID NO. 54

Table 2: Sequences of Kunitz domains, some of which inhibit human pKA.

	Amino-acid sequence	
	111111111122222222223333333333444444444455555555	
Ident	123456789012345678901234567890123456789012345678	SEQ ID NO.
DKI-7.1	rpdfcleppEtgpcRaAHPryfynakaglcEEfvyggcGakrnnfksaedcmrtcgga	SEQ ID NO. 55

Table 3 is above.

TABLE 8: Binding Data for Selected Kallikrein-binding Display-Phage.

Display-Phase(a)	Fraction Bound(b)	Relative Binding(c)
LACI	4.2×10^{-6}	1.0
BPTI	2.5×10^{-5}	6.0
KKI/3(a)	3.2×10^{-3}	761
KKI/3(b)	2.2×10^{-3}	524
KKII/3#5	3.9×10^{-3}	928
KKII/3#6	8.7×10^{-3}	2071

(a) Clonal isolates of display-phase. LACI-K1 is the parental molecule, BPTI (bovine pancreatic trypsin inhibitor) is a control and KKII/3 (5 and 6) and KKI/3(a and b) were selected by binding to the target protease, kallikrein.

(b) The number of pfu's eluted after a binding experiment as a fraction of the input number (10^{10} pfu's).

(c) Fraction bound relative to the parental display-phage, LACI-K1.

Table 9: Conservative and Semiconservative substitutions

Initial AA type	Category	Conservative substitution	Semi-conservative substitution
A	Small non-polar or slightly polar	G, S, T	N, V, P, (C)
C	free SH	A, M, L, V, I	F, G
	disulfide	nothing	nothing
D	acidic, hydrophilic	E, N, S, T, Q	K, R, H, A
E	acidic, hydrophilic	D, Q, S, T, N	K, R, H, A
F	aromatic	W, Y, H, L, M	I, V, (C)
G	Gly-only conformation	nothing	nothing
	"normal" conformation	A, S, N, T	D, E, H, I, K, L, M, Q, R, V
H	amphoteric aromatic	Y, F, K, R	L, M, A, (C)
I	aliphatic, branched β carbon	V, L, M, A	F, Y, W, G (C)
K	basic	R, H	Q, N, S, T, D, E, A
L	aliphatic	M, I, V, A	F, Y, W, H, (C)
M	hydrophobic	L, I, V, A	Q, F, Y, W, (C), (R), (K), (E)
N	non-polar hydrophilic	S, T, (D), Q, A, G, (E)	K, R
P	inflexible	V, I	A, (C), (D), (E), F, H, (K), L, M, N, Q, (R), S, T, W, Y
Q	aliphatic plus amide	N, E, A, S, T, D	M, L, K, R
R	basic	K, Q, H	S, T, E, D, A,
S	hydrophilic	A, T, G, N	D, E, R, K

Table 9: Conservative and Semiconservative substitutions			
Initial AA type	Category	Conservative substitution	Semi-conservative substitution
T	hydrophilic	A, S, G, N, V	D, E, R, K, I
V	aliphatic, branched β carbon	I, L, M, A, T	P, (C)
W	aromatic	F, Y, H	L, M, I, V, (C)
Y	aromatic	F, W, H	L, M, I, V, (C)

5

Changing from A, F, H, I, L, M, P, V, W, or Y to C is semiconservative if the new cysteine remains as a free thiol.

10

Changing from M to E, R, K is semiconservative if the ionic tip of the new side group can reach the protein surface while the methylene groups make hydrophobic contacts.

Changing from P to one of K, R, E, or D is semiconservative if the side group is on or near the surface of the protein.

15

Table 14: Definition of a Kunitz Domain (SEQ ID NO. 52)				
1	2	3	4	5
123456789012345678901234567890123456789012345678				
xxxxCxxxxxxxxGxCxxxxxxxxXXXXXXXXXXXXCxxFxxXGxCxxxXxxXxxxxxxxxCxxxCxxx				
Where:				
X1, X2, X3, X4, X58, X57, and X56 may be absent,				
X21 = Phe, Tyr, Trp,				
X22 = Tyr or Phe,				
X23 = Tyr or Phe,				
X35 = Tyr or Trp,				
X36 = Gly or Ser,				
X40 = Gly or Ala,				
X43 = Asn or Gly, and				
X45 = Phe or Tyr				

Table 15: Substitution to confer high affinity for pKA on KuDoms			
Position	Preferred	Allowed	Unlikely to work
10	Asp, Glu	Ala, Gly, Ser, Thr	Lys, Asn, (Arg, Cys, Phe, His, Ile, Leu, Met, Pro, Gln, Val, Trp, Tyr)
11	Asp, Gly, Ser, Val	Glu, Leu, Met, [Asn, Ile, Ala, Thr]	(Cys, Phe, His, Lys, Pro, Gln, Arg, Trp, Tyr)
12	Gly	(Other amino acids ONLY if C ₁₄ -C ₃₈ disulfide replaced by other amino acids.)	

Table 15: Substitution to confer high affinity for pKA on KuDoms			
Position	Preferred	Allowed	Unlikely to work
13	Arg, His, Pro, Asn, Ser	[Thr, Ala, Gly, Lys, Gln]	Phe, Tyr, Cys, Leu, Ile, Val, Asp (Glu, Met, Trp)
14	Cys	(Other amino acids ONLY if C ₃₈ also changed.)	
15	Arg, Lys	[Ala, Ser, Gly, Met, Asn, Gln]	(Cys, Asp, Glu, Phe, His, Ile, Leu, Pro, Thr, Val, Trp, Tyr)
16	Ala, Gly	[Ser, Asp, Asn]	(Cys, Glu, Phe, His, Ile, Lys, Leu, Met, Pro, Gln, Arg, Thr, Val, Trp, Tyr)
17	Ala, Asn, Ser, Ile	[Gly, Val, Gln, Thr]	Cys, Asp, Phe, His, Pro, Arg, Tyr, (Glu, Lys, Met, Trp)
18	His, Leu, Gln	[Ala,	Cys, Asp, Glu, Phe, Gly, Ile, Lys, Met, Asn, Pro, Arg, Ser, Thr, Val, Trp, Tyr
19	Pro, Gln, Leu	[Asn, Ile]	Ala, Glu, Gly, Met, Arg, Ser, Thr, Val, Trp, (Cys, Asp, Phe, His, Tyr)
20	Arg	Leu, Ala, Ser, Lys, Gln, Val	(Cys, Asp, Glu, Phe, Gly, His, Ile, Met, Asn, Pro, Thr, Trp, Tyr)

Table 15: Substitution to confer high affinity for pKA on KuDoms			
Position	Preferred	Allowed	Unlikely to work
21	Trp, Phe	[Tyr, His, Ile]	Cys, Leu (Ala, Asp, Glu, Gly, Lys, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val)
31	Glu	[Asp, Gln, Asn, Ser, Ala, Val, Leu, Ile, Thr]	(Arg, Lys, Cys, Phe, Gly, His, Met, Pro, Trp, Tyr)
32	Glu, Gln	[Asp, Asn, Pro, Thr, Leu, Ser, Ala, Gly, Val]	(Cys, Phe, His, Ile, Lys, Met, Arg, Trp, Tyr)
33	Phe	[Tyr]	other 18 excluded.
34	Ser, Thr, Ile	[Val, Ala, Asn, Gly, Leu]	Cys, Asp, Glu, Phe, His, Lys, Met, Pro, Gln, Arg, Trp, Tyr
35	Tyr	[Trp, Phe]	(other 17)
36	Gly	Ser, Ala	(other 17)
37	Gly	(Other amino-acid types allowed only if C14-C38 replaced by other types.)	
38	Cys	(Other amino acids ONLY if C ₁₄ also changed.)	
39	Gly, Glu, Ala	[Ser, Asp]	Other 15.

Under "Preferred", most highly preferred type are **bold**

Under "Allowed" are types not actually tested, but judged to be acceptable. Types shown in square brackets were allowed and not selected, but are so similar to types that were selected

that the type is unlikely to abolish pKA binding. Such types are not preferred, but pKA-binding proteins could have such types.

Under "Unlikely to work", types shown outside parentheses have been tried and no isolates had that type; types in parentheses have not been tested, but are judged to be unsuitable from
5 consideration of the types actually excluded.

TABLE 21: First Variegation of LACI-K1

	a	b	1	2	3	4	5	6	7	8	9	10
	A	E	M	H	S	F	C	A	F	K	A	D
5	gcc gag atg cat tcc ttc tgc gcc ttc aag gct gat											
	<u>NsiI</u>											
	I N											
	C H											
10	F S F Y											
	Y C L S L S											
	L P W P W P											
	H R Q R Q R											
	<u>I</u> T <u>M</u> T M T											
15	N V K V <u>K</u> V											
	L P A D A E A E											
	D	G	H R	C	K	A G	G	D G	G	R		
	11	12	13	14	15	16	17	18	19	20		
20	gat ggt cNt tgt aaa gSt NNt NNS NNg cgt											
	F	F	F	N	I	F	T	R	Q	C		
	21	22	23	24	25	26	27	28	29	30		
25	ttc ttc ttc aac atc ttc acg cgt cag tgc											
	<u>MluI</u>											
	Q E N H											
	M K C I											
	F S F Y											
30	Y C L S											
	L P W P											
	H R Q R											
	<u>I</u> T M T											
	N V K V											
35	A D A E											
	E Q	E Q	F	G W	Y	G	G	C	G D	G	N	Q
	31	32	33	34	35	36	37	38	39	40	41	42
	Sag Saa ttc NNS tac ggt ggt tgt NNS ggt aac cag											
	<u>BstEII</u>											

Table 21, continued

5 N R F E S L E E
 43 44 45 46 47 48 49 50
 |aac|cgg|ttc|gaa|tct|cta|gag|gaa|
 | BstBI | | XbaI |
 | AgeI |

10 51 52 53 54 55 56 57 58 59 60
 C K K M C T R D G A
 |tgt|aag|aag|atg|tgc|act|cgt|gac|ggc gcc
 | KasI |

- 15 The segment from *NsiI* to *MluI* gives 65,536 DNA sequences and 31,200 protein sequences. Second group of variegation gives 21,840 and 32,768 variants. This variegation can go in on a fragment having *MluI* and one of *AgeI*, *BstBI*, or *XbaI* ends. Because of the closeness between codon 42 and the 3'
- 20 restriction site, one will make a self-priming oligonucleotide, fill in, and cut with *MluI* and, for example, *BstBI*. Total variants are 2.726×10^9 and 8.59×10^9 . The DNA sequence has SEQ ID NO. 56. The amino acid sequence has SEQ ID NO. 57.

TABLE 23: Specificity Results

Protein displayed on M13 gIIIp	Immobilized enzyme tested				
	Plasmin	Thrombin	pKA	Trypsin	Trypsin, 2 washes
LACI-K1	1	1	1	1	1
KkII/3(D)	3.4	1.5	196.	2.	1.4
BPTI	88.	1.1	1.7	0.3	.8

- 35 Numbers refer to relative binding of phage display clones compared to the parental phage display.

The KkII/3(D)(Kallikrein) clone retains the parental molecule's affinity for trypsin. KkII/3(D) was selected for binding to pKA.

TABLE 24: Mat α *S. cerevisiae* expression vectors:Mat α 1 (Mf α 8)

5' - ... | K | R | P | R |
 | AAA | AGG | CCT | CGA | G... - 3'
 | StuI |
 | XhoI |

SEQ ID NO. 58
 SEQ ID NO. 59

Mat α 2 (after introduction of a linker into *StuI*-cut DNA)

10 amino acids: SEQ ID NO. 60
 K R E A A E P W G A . . L E
 5' | AAA | AGG | GAA | GCG | GCC | GAG | CCA | TGG | GGC | GCC | TAA | TAG | CTC | GAG | 3'
 | EagI | | StyI | KasI | | XhoI |
 DNA: SEQ ID NO. 61

Mat α -LACI-K1, amino acids: SEQ ID NO. 62, DNA: SEQ ID NO. 63

20 a b c d 1 2 3 4 5 6 7 8
 K R E A A E M H S F C A F K
 5' | AAA | AGG | GAA | GCG | GCC | GAG | atg | cat | tcc | ttc | tgc | gct | ttc | aaa |
 | EagI | | NsiI |

9 10 11 12 13 14 15 16 17 18 19 20
 A D D G P C K A I M K R
 | gct | gat | gaC | ggT | ccG | tgt | aaa | gct | atc | atg | aaa | cgt |
 | RsrII | | BspHI |

21 22 23 24 25 26 27 28 29 30
 F F F N I F T R Q C
 | ttc | ttc | ttc | aac | att | ttc | acG | cgt | cag | tgc |
 | MluI |

31 32 33 34 35 36 37 38 39 40 41 42
 E E F I Y G G C E G N Q
 | gag | gaA | ttC | att | tac | ggt | ggt | tgt | gaa | ggt | aac | cag |
 | EcoRI | | BstEII |

43 44 45 46 47 48 49 50
 N R F E S L E E
 |aac|cgG|ttc|gaa|tct|ctA|gag|gaa|
 | BstBI | | XbaI |
 | AgeI |

51 52 53 54 55 56 57 58 59 60
 C K K M C T R D G A
 45 |tgt|aag|aag|atg|tgc|act|cgt|gac|ggc|gcc|TAA|TAG|CTC|GAG|-3'
 | KasI | | XhoI |

We expect that Mat α pre sequence is cleaved before GLU₅-ALA₆-

Table 27: High specificity plasma Kallikrein inhibitors

LACI-K1 (SEQ ID NO. 3)

MHSFCAFKADDGPCKAIMKRFFFNIFTRQCEEFIYGGCEGNQNRFSLEECKKMCTRD

KKII/3#7 (SEQ ID NO. 11)

mhsfcafkaddgHckANHQRfffniftrqcEEfSyggcGgnqnrfesleeckkmctrd

KKII/3#7-K15A (SEQ ID NO. 64)

mhsfcafkaddghcAanhqrfffniftrqceefsyggcggnqnrfesleeckkmctrd

KK2/#13-R15A (SEQ ID NO. 65)

mhsfcafkADGgRcAGAHPrWffniftrqcEEfSyggcGgnqnrfesleeckkmctrd

KK2/#11-R15S (SEQ ID NO. 66)

mhsfcafkaddgpcSaahprwffniftrqceefsyggcggnqnrfesleeckkmctrd

Table 49

	Residue Number											
	10	11	12	13	14	15	16	17	18	19	20	21
LACI-K1	D	D	G	P	C	K	A	I	M	K	R	F
5 Consensus of KKII/3 selectants	d	d	g	H	c	k	A	N	H	Q	r	f
KK Library #2	NK DE	NI AD ST GV	g	FS YC LP HR IT NV AD G	c	KR	AG	NI AD ST GV	QL HP R	QL HP R	r	FW CL
KK2/#13	-	G	-	-	-	-	-	-	-	-	-	-
KK2/#14	-	G	-	-	-	-	-	-	-	-	-	-
10 KK2/#5	-	-	-	P	-	-	A	-	-	-	-	-
KK2/#11	-	-	-	P	-	-	A	-	-	-	-	-
KK2/#1	-	V	-	-	-	-	-	-	-	-	-	-
KK2/#4	-	V	-	-	-	-	-	-	Q	-	-	F
KK2/#6	-	-	-	S	-	-	A	-	-	L	-	-
15 KK2/#10	E	G	-	S	-	-	A	-	-	Q	-	-
KK2/#8	-	-	-	P	-	-	-	-	-	L	-	F
KK2/#3	-	-	-	H	-	-	-	-	L	-	-	-
KK2/#9	-	S	-	N	-	-	-	N	L	-	-	F
KK2/#7	-	S	-	-	-	-	-	N	-	Q	-	F
20 KK2/#12	-	G	-	-	-	-	A	I	Q	-	-	-
Consensus #2	D	D	g	R	c	R	G	A	H	P	r	W

Table 750: DNA that embodies Library KKF.

											N K
		M	H	S	F	C	A	F	K	A	D E
5		1	2	3	4	5	6	7	8	9	10
	5'-cctcct	atg	cat	tcc	ttc	tgc	gcc	ttc	aag	gct	RaS
		<u> NsiI </u>									
		F S									
10		Y C									
		L H									
		R I									
	I V	V T				V T	(M)	(K)			
	T A	A G				A S	L P	L P			
15	S G	D N				G D	Q R	R H			
	D N	G	P	C	K R	A G	I N	H	Q	R	
	11	12	13	14	15	16	17	18	19	20	
	RNt	ggt	NNt	tgt	aRa	gSt	RNt	cNS	cNS	cgt	
20	W L										
	F C	F	F	N	I	F	T	R	(SEQ ID NO. 69)		
	21	22	23	24	25	26	27	28			
	tKS	ttc	ttc	aac	atc	ttc	acg	cgt	tcctcc-3'	(SEQ ID NO. 67)	
		3'-g	ttg	tag	aag	tgc	gca	agggagg-5'	(SEQ ID NO. 68)		
25											
						<u> MluI </u>					

The *RsrII* and *BspHI* sites found in the parental LACI-K1 display gene (Table 6) are not present in Library KKF.

- 30 There are 1,536,000 amino-acid sequences and 4,194,304 DNA sequences. Met₁₈ and Lys₁₉ are not allowed in Library KKF.

Citations:

- ADEL86: Adelman *et al.*, *Blood* (1986) **68**(6)1280-1284.
- ALBR83a: Albrecht *et al.*, *Hoppe-Seyler's Z Physiol Chem* (1983), **364**:1697-1702.
- 5 ALBR83b: Albrecht *et al.*, *Hoppe-Seyler's Z Physiol Chem* (1983), **364**:1703-1708.
- ANBA88: Anba *et al.*, *Biochimie* (1988) **70**(6)727 -733.
- ANGL87: Angliker *et al.*, *Biochem J* (1987) **241**(3)871-5.
- AUER88: Auerswald *et al.*, *Bio Chem Hoppe-Seyler* (1988), **369**(Supplement):27-35.
- BALD85: Balduyck *et al.*, *Biol Chem Hoppe-Seyler* (1985) **366**:9-14.
- 10 BANE90: Baneyx & Georgiou, *J Bacteriol* (1990) **172**(1)491-494.
- BANE91: Baneyx & Georgiou, *J Bacteriol* (1991) **173**(8)2696-2703.
- BERN93: Berndt *et al.*, *Biochemistry* (1993) **32**:4564-70.
- BHOO92: Bhoola *et al.*, *Pharmacological Reviews* (1992) **44**(1)1-80.
- BROW91: Browne *et al.*, *GeneBank* entry M74220.
- 15 BROZ90: Broze *et al.*, *Biochemistry* (1990) **29**:7539-7546.
- COLM87: Colman *et al.*, Editors, **Hemostasis and Thrombosis**, Second Edition, 1987, J. B. Lippincott Company, Philadelphia, PA.
- COLM87a: Colman *et al.*, Chapter 1 of COLM87.
- DAVI79: Davis *et al.*, US Patent 4,179,337 (1979).
- 20 DENN94a: Dennis & Lazarus, *J Biological Chem* (1994) **269**:22129-22136.
- DENN94b: Dennis & Lazarus, *J Biological Chem* (1994) **269**:22137-22144.
- EIGE90: Eigenbrot *et al.*, *Protein Engineering* (1990), **3**(7)591-598.
- ELLI92: Ellis *et al.*, *Ann N Y Acad Sci* (1992) **667**:13-31.
- FIDL94: Fidler & Ellis, *Cell* (1994) **79**:185-188.
- 25 FRAE89: Fraedrich *et al.*, *Thorac Cardiovasc Surg* (1989) **37**(2)89-91.
- GARD93: Gardell, *Toxicol Pathol* (1993) **21**(2)190-8.
- GIRA89: Girard *et al.*, *Nature* (1989), **338**:518-20.
- GIRA91: Girard *et al.*, *J. BIOL. CHEM.* (1991) **266**:5036-5041.
- HOOV93: Hoover *et al.*, *Biochemistry* (1993) **32**:10936-43.
- 30 HORT91: Hortin & Trimpe, *J Biol Chem* (1991) **266**(11)6866-71.
- HYNE90: Hynes *et al.*, *Biochemistry* (1990), **29**:10018-10022.

- KEMP88b: Kemp & Bowen, *Tetrahedron Letts* (1988) 29:5077-5080.
- KIDO88: Kido *et al.*, *J Biol Chem* (1988), 263:18104-7.
- KIDO90: Kido *et al.*, *Biochem & Biophys Res Comm* (1990), 167(2)716-21.
- KLIN91: Kline *et al.*, *Biochem Biophys Res Commun* (1991) 177(3)1049-55.
- 5 LASK80: Laskowski & Kato, *Ann Rev Biochem* (1980), 49:593-626.
- LEAT91: Leatherbarrow & Salacinski, *Biochemistry* (1991) 30(44)10717-21.
- LOHM93: Lohmann & J Marshall, *Refract Corneal Surg* (1993) 9(4)300-2.
- LUCA83: Lucas *et al.*, *J Biological Chem* (1983) 258(7)4249-56.
- MANN87: Mann & Foster, Chapter 10 of COLM87.
- 10 MARC85: **Advanced Organic Chemistry, Third Edition** March, J, John Wiley and Sons, New York, 1985; ISBN 0-471-88841-9.
- MIYA85: Miyajima *et al.*, *Gene* (1985) 37:155-161.
- NEUH89: Neuhaus *et al.*, *Lancet* (1989) 2(8668)924-5.
- NOVO89: Novotny *et al.*, *J. BIOL. CHEM.* (1989) 264:18832-18837.
- 15 PARK86: Park & Tulinsky, *Biochemistry* (1986) 25(14)3977-3982.
- PUTT89: Putterman, *Acta Chir Scand* (1989) 155(6-7)367.
- ROBB87: Robbins, Chapter 21 of COLM87
- SCHE67: Schechter & Berger. *Biochem Biophys Res Commun* (1967) 27:157-162.
- SCHE68: Schechter & Berger. *Biochem Biophys Res Commun* (1968) 32:898-902.
- 20 SCHM87: Schmaier *et al.*, Chapter 2 in COLM87.
- SCHN86: Schnabel *et al.*, *Biol Chem Hoppe-Seyler* (1986), 367:1167-76.
- SHER89: Sheridan *et al.*, *Dis Colon Rectum* (1989) 32(6)505-8.
- TIAN92: Tian *et al.*, *Int J Pept Protein Res* (1992) 40(2)119-26.
- VAND91: van der Logt *et al.*, *BIOCHEMISTRY* (1991) 30:1571-1577.
- 25 VAND92: van Dijn *et al.*, *EMBO J* (1992) 11(8)2819-2828.
- VARA83: Varadi & Patthy, *Biochemistry* (1983) 22:2440-2446.
- VARA84: Varadi & Patthy, *Biochemistry* (1984) 23:2108-2112.
- WILS93: Wilson *et al.*, *Tetrahedron* (1993)49(17)3655-63.
- WUNT88: Wun *et al.*, *J. BIOL. CHEM.* (1988) 263:6001-6004.

CLAIMS

1. A kallikrein inhibiting protein which comprises a Kunitz Domain with residues numbered by reference to mature bovine pancreatic trypsin inhibitor, wherein, at each of the residues corresponding to the below identified residues of BPTI, one of the following allowed amino acids is found,

10	Asp, Glu
11	Asp, Gly, Ser, Val
13	His, Pro, Arg, Asn, Ser
15	Arg, Lys
16	Gly, Ala
17	Asn, Ser, Ala, Ile
18	His, Leu, Gln
19	Gln, Leu, Pro
21	Trp, Phe
31	Glu
32	Glu, Gln
34	Ser, Thr, Ile
39	Gly, Glu, Ala.

2. A plasma kallikrein inhibiting protein which comprises a sequence that is substantially homologous to a reference sequence being selected from the group consisting of

KKII/3 # 1, KKII/3 # 2, KKII/3 # 3, KKII/3 # 4, KKII/3 # 5, KKII/3 # 6, KKII/3 # 7, KKII/3 # 8, KKII/3 # 9, KKII/3 # 10, KK2/#11, KK2/#13, KK2/#1, KK2/#2, KK2/#3, KK2/#4, KK2/#6, KK2/#7, KK2/#8, KK2/#9, KK2/#10, KK2/#12, and KK2con1 as defined in Table 2.

3. A method of preventing or treating a disorder attributable to excessive kallikrein activity which comprises administering, to a human or animal subject who would benefit therefrom, a kallikrein-inhibitory amount of the protein or analogue of claim 1 or claim 2.

4. A method of assaying for kallikrein which comprises providing the protein or analogue of claim 1 or claim 2 in labeled or insolubilized form, and determining whether a complex of said protein and the kallikrein in a sample is formed.

5. A method of purifying kallikrein from a mixture which comprises providing the protein analogue of claim 1 in insolubilized form, and contacting the mixture with said insolubilized protein or analogue so that kallikrein in the mixture is bound.

THIS PAGE BLANK (USPTO)

(51) International Patent Classification ⁶ : C07K 14/81, A61K 38/57 C12Q 1/37, C12N 9/64	A3	(11) International Publication Number: WO 95/21601
		(43) International Publication Date: 17 August 1995 (17.08.95)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INTERNATIONAL SEARCH REPORT

Intern: al Application No

PCT/US 95/00299

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/81 A61K38/57 C12Q1/37 C12N9/64

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO-A-93 14122 (NOVONORDISK AS) 22 July 1993 see claims ---	1-5
Y	WO-A-93 14121 (NOVONORDISK AS) 22 July 1993 see claims ---	1-5
Y	WO-A-93 14120 (NOVONORDISK AS) 22 July 1993 see claims --- -/--	1-5

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

26 July 1995

Date of mailing of the international search report

1-6. 08. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Van der Schaal, C

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/US 95/00299

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>NATURE, vol. 338, 6 April 1989 pages 518-520, T. GIRARD ET AL 'Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor' see the whole document. -----</p>	1-5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/ 00299

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 3
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 3 is directed to a method treatment of the human bodies the search has been carried out and based on the alleged effect of the compound.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interns Application No

PCT/US 95/00299

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9314122	22-07-93	AU-B-	3346093
		CA-A-	2127246
		CZ-A-	9401644
		EP-A-	0621872
		FI-A-	943234
		JP-T-	7504891
		NO-A-	942549
		ZA-A-	9300096
WO-A-9314121	22-07-93	AU-B-	3345993
		CA-A-	2127249
		CZ-A-	9401649
		EP-A-	0621871
		FI-A-	943233
		NO-A-	942550
		ZA-A-	9300095
WO-A-9314120	22-07-93	AU-B-	3345893
		CA-A-	2127250
		CZ-A-	9401645
		EP-A-	0621870
		FI-A-	943232
		NO-A-	942551
		ZA-A-	9300097